Results 91 to 100 of about 36,503 (286)

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT‐ACS Emulation Using National Health Insurance Claims Data

Clinical Pharmacology &Therapeutics, EarlyView.
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang, Yee‐Jen Wu, Fang‐Ju Lin, Chien‐Chih Wu, Hsin‐Yi Huang, Chi‐Chuan Wang, Xiaojuan Li   +6 more
wiley   +1 more source

Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease

ARYA Atherosclerosis, 2011
BACKGROUND: The polymorphisms of cytochrome P450 2C19 (CYP2C19) gene are major prognostic factors for the response to clopidogrel therapy in patients with coronary artery diseases (CAD).
Arash Akhlaghi, Shahin Shirani, Naghmeh Ziaie, Omid Pirhaji, Majid Yaran, Golnoosh Shahverdi, Nizal Sarrafzadegan, Alireza khosravi, Elham khosravi   +8 more
doaj  

CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt

Journal of Epidemiology and Global Health, 2023
Background Cardiovascular diseases (CVDs) are considered a leading cause of death worldwide. Allelic variation in the CYP2C19 gene leads to a dysfunctional enzyme, and patients with this loss-of-function allele will have an impaired clopidogrel ...
Ahmed Shawky, Hussein Sabit, Mahmoud Nazih, Khalid Baraka, Mokhtar El-Zawahry   +4 more
doaj   +1 more source

Towards the clinical implementation of pharmacogenetics in bipolar disorder. [PDF]

, 2014
BackgroundBipolar disorder (BD) is a psychiatric illness defined by pathological alterations between the mood states of mania and depression, causing disability, imposing healthcare costs and elevating the risk of suicide.
A Berghofer, A Heils, A Koski, A Serretti, A Serretti, A Serretti, A Szczepankiewicz, A Yu, AA Nierenberg, AK Malhotra, AL Zackrisson, B Alsina, B Kremeyer, C Cordon-Cardo, C Kawanishi, C O’Dushlaine, C Sears, CA Grimes, CC Zai, CE Begley, CH Chen, DA Mrazek, DE Adkins, DJ Smith, DK Hall-Flavin, DK Hall-Flavin, DL Braff, E Lessard, E Schaeffeler, EB Binder, EB Brown, EG Jonsson, EJ Peters, EK Green, EM Penas-Lledo, EM Penas-Lledo, EN Smith, ER Mardis, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, F Asztely, F Benedetti, F Czerwensky, F Holsboer, F Mamdani, FJ Gonzalez, FJ McMahon, FM Daray, FP Bymaster, FP Guengerich, FR Sallee, G Shaltiel, G Turecki, GE Simon, GENDEP Investigators, MARS Investigators, STAR*D Investigators, GR Lewin, GS Malhi, GS Sachs, H Pei, HA Garriock, HK Kroemer, I Johansson, IC Gray, J Brockmoller, J de Leon, J de Leon, J de Leon, J de Leon, J Kirchheiner, J Kirchheiner, J Thome, J Winner, JA Engelman, JA Johnson, JA Lieberman, JC Ballenger, JC Chambers, JC Stingl, JE Kootstra-Ros, JE Sarginson, JK Rybakowski, JK Rybakowski, JM Beaulieu, John R Kelsoe, JP Zhang, JP Zhang, JR Kelsoe, JS Leeder, JT Groves, K Herrlin, K Hodgson, K Yoshii, KG Mountjoy, KL Kopnisky, KR Crews, KW Lobello, L Bertilsson, L Michelon, L Tondo, LA Smith, LN Yatham, LV Kessing, M Adli, M Dmitrzak-Weglarz, M Gex-Fabry, M Ingelman-Sundberg, M Man, M Ramsjo, M Sanford, M Tseng, M Uhr, MA Kohli, MA Martin, MD Ritchie, ME van den Akker-van Marle, MH Tsai, Michael J McCarthy, MJ Arranz, MJ McCarthy, MJ Neville, ML Dahl, Naji C Salloum, OL de Klerk, OV Olesen, P Grof, P Huezo-Diaz, P Sklar, PS Klein, Psychiatric GWAS Consortium Bipolar Disorder Working Group, R Calati, R Hashimoto, RA Philibert, RC Kessler, RH Perlis, RH Perlis, RH Perlis, RH Perlis, RH Weisler, RJ Loos, RM Hirschfeld, RM Post, RS Seelan, S Horstmann, S Kapur, S Kapur, S Mallal, S Paddock, S Steinberg, S Ulrich, SC Sim, SG Leckband, SH Sindrup, SI Hung, SJ Gardiner, SL McElroy, Susan G Leckband, SV Ambudkar, T Bremer, T Masui, T Rau, T Ritchie, T Suppes, TD Gould, TE Klein, TL Horvath, V De Luca, VL Ellingrod, W Steimer, WB Denny, WH Chung, YF Lin, YF Zou, Z Wang, Z Wang   +172 more
core   +3 more sources

Utilizing pharmacogenomics to improve students' self‐perception on the interprofessional competencies of roles and responsibilities, and teams and teamwork

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, EarlyView.
Abstract Introduction Pharmacogenomics (PGx) is an emerging discipline with the potential to revolutionize personalized medicine, but its successful implementation requires interprofessional collaboration. To address this need, a virtual interprofessional education (IPE) session was designed for student pharmacists and medical students to engage in a ...
Amanda Brown, Moom R. Roosan, Robert Goldsteen, Scott D. Ochs, Reza Taheri   +4 more
wiley   +1 more source

Clopidogrel Use and CYP2C19 Genotypes in Patients Undergoing Vascular Intervention Procedure: A Hospital-Based Study

Pharmacogenomics and Personalized Medicine, 2022
Yi-Ju Liao,1 Tzu-Hung Hsiao,2– 4 Ching-Heng Lin,2,3,5,6 Chun-Sheng Hsu,7– 10 Yen-Lin Chang,1,8 Yu-Wei Chen,11 Chiann-Yi Hsu,2,12 Yi-Ming Chen,2,10,13– 15,* Ming-Fen Wu1,* 1Department of Pharmacy, Taichung Veterans General Hospital, Taichung ...
Liao YJ, Hsiao TH, Lin CH, Hsu CS, Chang YL, Chen YW, Hsu CY, Chen YM, Wu MF   +8 more
doaj  

CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. [PDF]

PLoS ONE, 2013
Several studies have indicated that CYP2C19 loss-of-function polymorphisms have a higher risk of stent thrombosis (ST) after percutaneous coronary interventions (PCIs).
Xiang Xie, Yi-Tong Ma, Yi-Ning Yang, Xiao-Mei Li, Xiang Ma, Zhen-Yan Fu, Ying-Ying Zheng, Bang-Dang Chen, Fen Liu   +8 more
doaj   +1 more source

The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population [PDF]

, 2017
The present study was designed to investigate whether common single-nucleotide polymorphisms (SNP) of CYP2C gene subfamily such as CYP2C8 (rs7909236 and rs1934953), CYP2C9 (rs9332242), and CYP2C19 (rs4244285) are associated with susceptibility to EH in ...
Bocharova, A., Bykanova, M., Polonikov, A., Ponomarenko, I., Sirotina, S.   +4 more
core   +1 more source

In Vitro Assessment of Drug‐Induced Liver Injury Using Three‐Dimensional Cultured HepaSH Cells Derived From Chimeric Mouse Model With Humanized Liver

Journal of Applied Toxicology, EarlyView.
ABSTRACT Drug‐induced liver injury (DILI) is a serious adverse event and a common cause of postmarketing drug withdrawal. Despite nonclinical assessments of DILI risk, which are predominantly conducted in experimental animals, DILI remains a frequent adverse event, highlighting the need to improve nonclinical assessments.
Xingming Liu, Yuichiro Higuchi, Yuta Sakamoto, Shota Yanagida, Shotaro Uehara, Hiroshi Suemizu, Yasunari Kanda, Hiroyuki Kawagishi   +7 more
wiley   +1 more source

Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions

Pharmacogenomics and Personalized Medicine, 2021
Chiara Jeiziner,1 Céline K Stäuble,1,2 Markus L Lampert,1 Kurt E Hersberger,1 Henriette E Meyer zu Schwabedissen2 1Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland ...
Jeiziner C, Stäuble CK, Lampert ML, Hersberger KE, Meyer zu Schwabedissen HE   +4 more
doaj